We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Device-Generating Hydroxyl Radicals Kills Superbugs in Hospitals

By Labmedica staff writers
Posted on 30 Jan 2008
Air disinfection by hydroxyl radicals is being used to fight methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, Novovirus, and Escherichia Coli in hospitals.

It has long been known that these superbugs cannot survive outdoors because they are destroyed by the germ-killing properties of fresh-air. More...
However, in enclosed spaces such as hospital wards, surgeries, and offices, these microorganisms persist and, until now, there has been no safe or easy way to kill them.

Scientists proved that the naturally occurring element in fresh-air was also a key part of the human immune system. They identified the "Open Air Factor” as the hydroxyl radical (OH). Hydroxyl radicals are generated in a number of reactions essential to life. In the body, hydroxyl radicals are produced by cells to kill invading pathogens as an essential part of the body's natural defense systems. In the fresh air, hydroxyl radials are produced by the reaction of ozone and olefins, the natural scents of flowers and plants.

British scientists and engineers created a new device, the AD, which can generate hydroxyl radicals in enclosed places, in a way that is entirely safe to humans but which kills air-borne bacteria and viruses. AD is made of aerospace-grade aluminum alloys and exceeds all necessary safety requirements. Sunderland Royal (Sunderland, UK) is one of a number of National Health Service (NHS; UK) hospitals beginning to use AD as a central element in their fight against air-borne super bugs.

Tests conducted by the Health Protection Agency (HPA) and other independent experts prove that a heavily contaminated room is cleaned to below detectable levels of pathogens within a matter of minutes, and unlike standard cleaning of surfaces, the hydroxyl radicals continue to be just as effective in destroying superbugs when an infected person or material subsequently enters the room.

AD is a product of Inov8 Science (Buckingham, UK), a wholly-owed subsidiary of Mid-States Plc (Buckingham, UK), Mike Heath managing, director of Mid-States said, "We know that superbugs cannot survive in fresh-air, but clearly it is not practical to have the windows open all the time. The AD allows us to bring the outdoors indoors. We have developed a device that is economic, easy to use, and can operate continuously in rooms full of people. The AD is the product of over 40 years of British research and we believe it can be instrumental in the battle to beat hospital acquired infection.”

Initially, AD will be exclusively available to the UK healthcare industry.


Related Links:
Health Protection Agency
National Health Service
Inov8 Science Ltd

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.